ARCA biopharma to Present at the Sidoti & Company Fall 2017 Conference
September 21 2017 - 8:30AM
ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company
applying a precision medicine approach to developing
genetically-targeted therapies for cardiovascular diseases, today
announced that it will present a corporate overview at the Sidoti
& Company Fall 2017 Conference, taking place September 28, 2017
in New York, New York.
Date: |
|
Thursday, September 28,
2017 |
Time: |
|
3:40 p.m. (Eastern
Time) |
Presenter: |
|
Thomas Keuer, Chief
Operating Officer |
Webcast/Presentation: |
|
The live webcast will
be available at http://www.investorcalendar.com/event/20225
and
http://arcabio.com/investors/investor-presentations/. ARCA’s
corporate investor presentation will be posted in the Investor
Relations section of its website (www.arcabio.com). |
Replay
Information: |
|
A replay of the webcast
is expected to be available approximately two hours after the
presentation on September 28, 2017, and will remain available for
90 days. The replay can be accessed at
http://www.investorcalendar.com/event/20225. |
About ARCA biopharma
ARCA biopharma is dedicated to developing
genetically-targeted therapies for cardiovascular diseases through
a precision medicine approach to drug development. ARCA’s
lead product candidate, GencaroTM (bucindolol hydrochloride), is an
investigational, pharmacologically unique beta-blocker and mild
vasodilator being developed for the potential treatment of patients
with atrial fibrillation and HFrEF, currently in a Phase 2B
clinical trial. ARCA has identified common genetic variations
that it believes predict individual patient response to Gencaro,
giving it the potential to be the first genetically-targeted atrial
fibrillation prevention treatment. ARCA has a collaboration
with Medtronic, Inc. for support of the GENETIC-AF trial. The
Gencaro development program has been granted Fast Track designation
by the FDA. For more information, please visit
www.arcabio.com.
Safe Harbor Statement
This press release and the anticipated
presentation contain "forward-looking statements" for purposes of
the safe harbor provided by the Private Securities Litigation
Reform Act of 1995. These statements include, but are not
limited to, statements regarding, the potential timeline for
GENETIC-AF trial activities, potential timing for the announcement
of topline data for the Phase 2B GENETIC-AF trial, the sufficiency
of ARCA’s capital to support its operations, the expected features
and characteristics of Gencaro, including the potential for genetic
variations to predict individual patient response to Gencaro,
Gencaro’s potential to treat AF, future treatment options for
patients with AF, and the potential for Gencaro to be the first
genetically-targeted AF prevention treatment. Such statements
are based on management's current expectations and involve risks
and uncertainties. Actual results and performance could
differ materially from those projected in the forward-looking
statements as a result of many factors, including, without
limitation, the risks and uncertainties associated with: ARCA’s
financial resources and whether they will be sufficient to meet its
business objectives and operational requirements; results of
earlier clinical trials may not be confirmed in future trials; the
protection and market exclusivity provided by ARCA’s intellectual
property; risks related to the drug discovery and the regulatory
approval process; and, the impact of competitive products and
technological changes. These and other factors are identified
and described in more detail in ARCA’s filings with the Securities
and Exchange Commission, including without limitation ARCA’s annual
report on Form 10-K for the year ended December 31, 2016, and
subsequent filings. ARCA disclaims any intent or obligation
to update these forward-looking statements.
Investor & Media
Contact:Derek Cole
720.940.2163derek.cole@arcabio.com
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From Apr 2023 to Apr 2024